

Acta Medica Okayama

Volume 56, Issue 4

2002

Article 4

AUGUST 2002

Mutations in the hepatitis B virus preS2 region and abrogated receptor activity for polymerized human albumin.

Junichi Kondo, *Okayama University*
Hiroyuki Shimomura, *Okayama University*
Shin-ichi Fujioka, *Okayama University*
Yoshiaki Iwasaki, *Okayama University*
Shinjiro Takagi, *Okayama University*
Yasuhiro Ohnishi, *Okayama University*
Hideyuki Tsuji, *Okayama University*
Kosaku Sakaguchi, *Okayama University*
Kazuhide Yamamoto, *Okayama University*
Takao Tsuji, *Okayama University*

Mutations in the hepatitis B virus preS2 region and abrogated receptor activity for polymerized human albumin.*

Junichi Kondo, Hiroyuki Shimomura, Shin-ichi Fujioka, Yoshiaki Iwasaki, Shinjiro Takagi, Yasuhiro Ohnishi, Hideyuki Tsuji, Kosaku Sakaguchi, Kazuhide Yamamoto, and Takao Tsuji

Abstract

The preS2 region of the hepatitis B virus (HBV) has been reported to have human polymerized albumin receptor (PAR) activity, which correlates with viral replication. Here, we studied the genomic sequence of the preS region from rare patients lacking PAR activity, despite active viral replication. PAR and DNA polymerase activity was identified in 178 HBe antigen-positive HBV carriers, and a significant correlation between 2 markers was shown, except in 2 hepatitis patients lacking PAR activity. Nucleotide sequences of the preS region of HBV from both patients were examined by direct sequencing of PCR products. In one patient, a 45-base deletion was found to overlap half of the putative polymerized human albumin binding site in the preS2 region. In the other patient, a point mutation at the first nucleotide of the start codon of the preS2 region of HBV was found. There was no such genomic change in the 3 control HBV sequences. These results indicate that the preS2 region is necessary for binding of polymerized human albumin, and this is the first report of naturally existing mutant virus with no or low PAR activity.

KEYWORDS: hepatitis B virus, preS region, polymerized albumin receptor, genetic mutation, genetic deletion

*PMID: 12199524 [PubMed - indexed for MEDLINE]

Original Article

Mutations in the Hepatitis B Virus PreS2 Region and Abrogated Receptor Activity for Polymerized Human Albumin

Junichi Kondo, Hiroyuki Shimomura*, Shin-ichi Fujioka, Yoshiaki Iwasaki, Shinjiro Takagi, Yasuhiro Ohnishi, Hideyuki Tsuji, Kosaku Sakaguchi, Kazuhide Yamamoto, and Takao Tsuji

Department of Medicine and Medical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama, 700-8558, Japan

The preS2 region of the hepatitis B virus (HBV) has been reported to have human polymerized albumin receptor (PAR) activity, which correlates with viral replication. Here, we studied the genomic sequence of the preS region from rare patients lacking PAR activity, despite active viral replication. PAR and DNA polymerase activity was identified in 178 HBe antigen-positive HBV carriers, and a significant correlation between 2 markers was shown, except in 2 hepatitis patients lacking PAR activity. Nucleotide sequences of the preS region of HBV from both patients were examined by direct sequencing of PCR products. In one patient, a 45-base deletion was found to overlap half of the putative polymerized human albumin binding site in the preS2 region. In the other patient, a point mutation at the first nucleotide of the start codon of the preS2 region of HBV was found. There was no such genomic change in the 3 control HBV sequences. These results indicate that the preS2 region is necessary for binding of polymerized human albumin, and this is the first report of naturally existing mutant virus with no or low PAR activity.

Key words: hepatitis B virus, preS region, polymerized albumin receptor, genetic mutation, genetic deletion

Hepatitis B virus (HBV) has an envelope consisting of 3 glycoproteins coded by parts of the HBV genome, all sharing the C-terminal sequence, which contains the major surface antigen (HBsAg). Of these, the N-terminal sequence of the middle surface protein is encoded by the preS2 region located just upstream of the S region of the HBV genome and is functionally associated with binding activity of HBV surface proteins to polymerized human albumin through putative polymerized albumin receptors (PAR) both on HBV and hepatocytes

[1]. It has therefore been suggested that HBV may enter into hepatocytes through this species- and organ-specific binding machinery. Also the preS1 region has been reported as a principal binding site for hepatocytes [2]. Bruss [3] has reported that hepatitis B virus particles contain 2 forms of the L protein: an external (e-preS) and internal (i-preS) pre-S domain. It is thus indicated that the external preS domain is involved in binding to virus receptors. As such, the preS region of the HBV genome appears to be important in the first phase of HBV's entry pathway into the hepatocyte.

We have previously demonstrated that PAR activity in serum of the HBV carrier is closely correlated with serum HBV DNA polymerase [4] levels, which reflect

Received December 11, 2001; accepted January 8, 2002.

*Corresponding author. Phone: +81-86-235-7219; Fax: +81-86-225-5991
E-mail: hshimomu@md.okayama-u.ac.jp (H. Shimomura)

viral replication. Here, we have defined the amount of polymerized human albumin bound to HBs antigen as PAR activity [4]. While PAR activity is a clinically useful tool in evaluating the viral replicative state in HBV carriers [5], we found 2 patients with active viral replication but less PAR activity in 178 HBe antigen-positive carriers. To clarify this dissociation, we analyzed in the present study the genomic sequences of the pre-S region of HBV from these patients, finding that genomic changes in this region may be directly linked to the biological function of this viral protein.

Materials and Methods

Patients. All patients, who visited our hospital between September 1987 and December 1994 and were positive for HBs antigen and HBe antigen were enrolled in this study. During this period, 178 patients were found to be HBe antigen-positive out of 256 patients positive for the HBs antigen. Their sera of these patients was collected and stored at -20°C until use.

HBV markers. HBsAg was determined by a reverse passive hemagglutination test (SERODIA-HBs; Fujirebio Inc., Tokyo, Japan). HBeAg was determined by radioimmunoassay (HBe RIAKIT II; Dainabot, Tokyo, Japan). HBV DNA-polymerase was determined by Kaplan's method [6]. PAR activity was determined by the method reported by Tsuji [4], with the optical density being measured at 492 nm in Photo-ELISA I (Organon, Oss, the Netherlands) and expressed as arbitrary unit. Negative controls showed a range of 0.04–0.23.

Sequencing of the preS1 and preS2 regions of HBV. Nucleotide sequences of the preS1 and preS2 regions of HBV were determined from patient serum by direct sequencing of PCR products. In brief, DNA was extracted from 100 μl of serum by the SDS-proteinase K method [7]. PreS1 and preS2 regions of HBV DNA were amplified by 45 cycles of polymerase chain reaction (PCR) using a sense primer (5'-GGGTACCATATTCTTGGGA-3', 2814–2833) and an anti-sense primer (5'-GTCCTAGGAATCCTGATG-3', 185–168) [8]. PCR products were purified using a SUPREC-2 column (Takara, Ohtsu, Japan) and se-

quenced with an ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer, Foster City, CA, USA) in a 373A DNA Sequencing System (Applied Biosystems Japan, Chiba, Japan) [9].

Results

Correlation between DNA-P and PAR. DNA-polymerase (DNA-P) and PAR activity was determined in one serum specimen from each of the 178 HBe antigen-positive patients and is plotted in Fig. 1. These 2 parameters were found to be correlated ($r^2 = 0.533$, $P < 0.001$).

In this population, 2 patients (patients 1 and 2 in Fig. 1) were found to be outside of this correlation. We then examined the genomic sequences of the preS regions of HBV from these 2 patients, with another 3 patients (patients 3, 4, and 5 in Fig. 1) as a control. The clinical backgrounds of studied patients are given in Table 1. Although alanine aminotransferase (ALT) and DNA-P levels fluctuated in patients 1 and 2, as seen in control patients, the PAR activity of patients 1 and 2 remained low. Subtypes of HBV were adr, except for the adwr subtype in patient 2. These 5 patients had chronic hepatitis histologically diagnosed by perioneoscopic liver biopsy performed under patients' written informed consent.

Sequence of the HBV preS region. Nucleotide sequences of the preS regions of HBV from




Fig. 1 Correlation between serum PAR and HBV DNA polymerase activities of HBe antigen-positive HBs antigen carriers. Numbers with arrows indicate patients selected for this study.

Footnote: This work was presented in part at the 49th Annual Meeting of the American Association for the Study of Liver Diseases on November 6–10, 1998, at Chicago, USA.

patients 1 and 2 along with control patients and subtype adr (Genebank accession number M38454) are shown in Fig. 2. Compared with the adr wild-type sequence, several point mutations were detected: 5 in patient 1; 8 in patient 2; 5 in patient 3; 7 in patient 4; and 2 in patient 5. Also, patient 1 had 45 base deletions in the preS2 region, which spans 5' upstream to the middle of the putative polymerized human albumin binding site [10].

Amino acid sequences were deduced from nucleotide sequences (Fig. 3). The nucleotide point mutations seen in patients 3, 4, and 5 were silent, meaning that there was no amino acid replacement. In contrast, in patient 1 there were 2 missense mutations (⁹⁰Val to ⁹⁰Ala in preS1 region; ¹⁵⁹Ser to ¹⁵⁹Leu in preS2 region) and 15 amino acid-long deletions. In the case of patient 2, there were 3 missense mutations, one of which was located at the first codon of the preS2 region. The start codon (ATG, ¹²⁰Met) of the preS2 region was changed to ¹²⁰Val (GTG), and others were in the preS1 region: ⁷⁷Tryp to ⁷⁷Cys and ⁹⁰Val to ⁹⁰Ala.

To determine whether the mutations detected above were consistent in these patients, the same regions from sera collected at different times were sequenced: 2 and 4 years later in patient 1; 1, 2, 4, and 5 years later in patient 2. The nucleotide sequences from these samples were the same as the oldest ones shown in Fig. 2 (data not shown).

Discussion

Genomic mutations of several regions of the HBV genome have been reported thus far. In the envelope protein, the nucleotide sequence of the antigen-

determining site of the S region is changed to a missense mutation, resulting in different antigenic properties. This mutation is referred to as an escape mutant, as this clone was discovered in successful HBs antigen vaccinees and escaped from neutralizing antibodies induced by the vaccine [11, 12]. Mutations in the preS region has also been reported [13–17].

The preS2 region consists of 55 amino acids, and its function and clinical significance has not yet been elucidated. It has, however, been hypothesized that this region might be essential for HBV to bind and enter into hepatocytes via polymerized human albumin in a specific manner [18–21]. The mutants found in our patients may relate to this function, although additional studies of preS proteins and *in vitro* expression will be necessary to confirm this hypothesis.

In patient 1 of our study, a part of the deletion of nucleotide sequences overlapped the putative PAR site, possibly destroying PAR function. In patient 2, we found a start codon mutant of preS2. The start codon mutant could result in an absence of preS2 protein. Although the preS2 sequence was contained in the large HBs antigen protein, which was translated from the preS1 start codon through preS1 and preS2, PAR function was lost in this mutant. As such PAR function might require the constitutional structure of this region.

In Santantonio's study, five out of 22 Italian HBV carriers had HBV without expression of the preS2 protein. Four showed a deletion of the start codon, and another had a point mutation of the start codon of the preS2 region [10]. Similar mutants have been reported by Fernholz [22] in chronic HBV carriers.

Interestingly, Pollicino [17] has reported a family cluster of fulminant hepatitis possibly caused by the preS2 start codon mutant. They have suggested that the absence of preS2 protein in early events in infection may lead to a failure to neutralize the virus and more severe liver damage. Our patients were chronic HBV carriers, and this sequence should be examined in acute hepatitis patients. No information regarding the relationship between mutant and PAR activity has been provided by the above studies, so the present results are the first to relate to both.





PAR activity has been used as a useful marker to determine the state of viral replication and disease activity of chronic hepatitis B and HBV carriers [5]. During the clinical course of hepatitis B, correlations were found between serum PAR activity and DNA-P in individual

Table 1 Clinical background of patients

	Age/sex	Range*			Subtype
		ALT	PAR (unit)	DNA-P (cpm)	
Patient 1	38/M	27–120	0.04– 1.48	4– 716	adr
Patient 2	41/M	41–525	0.24– 0.65	123– 2723	adwr
Patient 3	50/F	28– 48	10.20–17.29	151– 4522	adr
Patient 4	40/M	18–313	1.15–16.2	10–44346	adr
Patient 5	42/M	28–709	0.11–15.62	3–66553	adr

*, range of ALT, PAR, and DNA-P in studied patients during the observation period (1.4 years for patient 1, 1.9 years for patient 2). The sampling times for each patient were as follows: 23 in patient 1; 17 in patient 2; 19 in patient 3; 41 in patient 4; 82 in patient 5.

```

           PreS1
M38454 1:  ATGGGAGGTTGGTCTTCCAAACCTCGACAAGGCATGGGGACGAATCTTCTGTTCCTCAAT
Patient 1 1: .....T.....
2 1: .....
3 1: .....
4 1: .....
5 1: .....T.....
*****
M38454 61: CCTCTGGGATTCCTTCCCGATCACCAGTTGGACCCTGCGTTCGGAGCCAACCTCAAACAAT
1 61: .....T.....
2 61: .....T.....
3 61: .....
4 61: .....
5 61: .....
*****
M38454 121: CCAGATTGGGACTTCAACCCCAACAAGGATCACTGGCCAGAGGCAAATCAGGTAGGAGCG
1 121: .....
2 121: .....
3 121: .....
4 121: .....
5 121: .....
*****
M38454 181: GGAGCATTCGGGCCAGGGTTCACCCACACACGGCGTCTTTTGGGGTGGAGCCCTCAG
1 181: .....A.....
2 181: .....A.....C.....
3 181: .....C.....
4 181: .....C.....
5 181: .....
*****
M38454 241: GCTCAGGGCATATTGACAACAGTCCAGTAGCACCTCCTCCTGCCTCCACCAATCGGCAG
1 241: .....C.....
2 241: .....C.....
3 241: .....C...G...C.....
4 241: .....C...G.....
5 241: .....
*****
M38454 301: TCAGGAAGACAGCCTACTCCCATCTCTCCACCTCTAAGAGACAGTCATCCTCAGGCCATG  PreS2
1 301: .....
2 301: .....G.....G..
3 301: .....
4 301: .....
5 301: .....
*****
M38454 361: CAGTGGAACTCCACAACATTCACCAAGCTCTGCTAGACCCAGAGTGAGGGCCTATAC
1 361: .....
2 361: .....T.....T
3 361: .....T.....T
4 361: .....T.....T
5 361: .....T.....
*****
M38454 421:  TTTCCTGCTGGTGGCTCCAGTTCGGGAACAGTAAACCTGTTCGACTACTGCCTCACCC
1 421: ---.....T.....
2 421: .....
3 421: .....
4 421: .....A.....
5 421: C.....
*****
M38454 481: ATATCGTCAATCTTCTCGAGGACTGGGGACCCCTGCACCGAAC
1 481: .....
2 481: .....
3 481: .....
4 481: .....G.....
5 481: .....
*****

```

Fig. 2 Nucleotide sequence of the HBV preS region. Sequence of wild-type adr (Genebank M38454) and those of 5 patients are aligned. Putative sites for binding with polymerized albumin [10] are indicated by a shaded box.



Fig. 3 Amino acid sequence of the PreS region deduced from the nucleotide sequences shown in Fig. 2. Deletion of amino acid sequences is indicated as a shaded box.

patients, except patients 1 and 2, in the present study (data not shown).

We found deviations from this significant correlation between PAR activity and HBV replication to be relatively rare (1.1% of 178 HBe antigen-positive HBV carriers) in this study, and the clinical significance of PAR activity did not change.

The subtype of HBV was adr in patient 1 and adwr in patient 2. A previous study of point mutations of compound subtypes [23] indicated no mutations at the start codon of preS2 in adwr, so this mutation does not appear to be related to subtype.

In conclusion, a mutation at the start codon or deletion in the preS2 region is suggested to cause a loss or lowering of PAR activity. The clinical significance of these mutants should be examined further.

Acknowledgments. We would like to thank Drs. Hiroshi Nakagawa, Kozo Fujio, Toshimi Hasui, Masaki Wato, and Yasushi Ishii for their valuable support and advice, and Ms. Hiroko Kajitani and Ms. Toshie Ishii for their technical support regarding HBV genome analysis and the PAR assay. We also appreciate Dr. Toshitaka Ohashi's (Department of Molecular Biology and Biochemistry, Okayama University) technical advice regarding the sequencing method.

References

1. Michalak TI and Bolger GT: Characterization of the binding sites for glutaraldehyde-polymerized albumin on purified woodchuck hepatocyte plasma membranes. *Gastroenterology* (1989) **96**, 153-166.
2. Theilmann L and Goeser T: Interactions of hepatitis B virus with hepatocytes: Mechanism and clinical relevance. *Hepatogastroenterology* (1991) **38**, 10-13.
3. Bruss V and Vieluf K: Functions of the internal pre-S domain of the large surface protein in hepatitis B virus particle morphogenesis. *J Virol* (1995) **69**, 6652-6657.
4. Tsuji T: Albumin receptors on HBsAg particles and subsequent seroconversion designate HBeAg-positive patients among chronic active liver disease patients. *Acta Med Okayama* (1984) **38**, 89-92.
5. Tsuji T: Detection of serum albumin receptor in hepatitis B virus carriers by enzyme-linked immunosorbent assay. *Gastroenterol Jpn* (1982) **17**, 585-590.
6. Kaplan PM, Greenman RL, Gerin JL, Purcell RH and Robinson WS: DNA polymerase associated with human hepatitis B antigen. *J Virol* (1973) **12**, 995-1005.
7. Kaneko S, Feinstone SM and Miller RH: Rapid and sensitive method for the detection of serum hepatitis B virus DNA using the polymerase chain reaction technique. *J Clin Microbiol* (1989) **27**, 1930-1933.
8. Thiers V, Nakajima E, Kremsdorf D, Mack D, Schellekens H, Driss F, Goudeau A, Wands J, Sninsky J, Tiollais P and Brechot C: Transmission of hepatitis B from hepatitis-B-seronegative subjects. *Lancet* (1988) **2**, 1273-1276.
9. Fujioka S, Shimomura H, Fujio K, Ikeda F, Miyake M, Ishii Y, Itoh M, Sakaguchi K and Tsuji T: Two cases of chronic hepatitis B with emergence of lamivudine-resistant virus during long-term therapy. *Hepatology Research* (1999) **13**, 97-104.
10. Santantonio T, Jung MC, Schneider R, Fernholz D, Milella M, Monno L, Pastore G, Pape GR and Will H: Hepatitis B virus genomes that cannot synthesize pre-S2 proteins occur frequently and as dominant virus populations in chronic carriers in Italy. *Virology* (1992) **188**, 948-952.
11. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ and Thomas HC: Vaccine-induced escape mutant of hepatitis B virus. *Lancet* (1990) **336**, 325-329.
12. Moriyama K, Nakajima E, Hohjoh H, Asayama R and Okochi K: Immunoselected hepatitis B virus mutant. *Lancet* (1991) **337**, 125.
13. Gerken G, Kremsdorf D, Capel F, Petit MA, Dauguet C, Manns MP, Meyer zum Buschenfelde KH and Brechot C: Hepatitis B defective virus with rearrangements in the preS gene during chronic HBV infection. *Virology* (1991) **183**, 555-565.
14. Melegari M, Bruno S and Wands JR: Properties of hepatitis B virus pre-S1 deletion mutants. *Virology* (1994) **199**, 292-300.
15. Nakajima E, Minami M, Ochiya T, Kagawa K and Okanou T: PreS1 deleted variants of hepatitis B virus in patients with chronic hepatitis. *J Hepatol* (1994) **20**, 329-335.
16. Pult I, Chouard T, Wieland S, Klemenz R, Yaniv M and Blum HE: A hepatitis B virus mutant with a new hepatocyte nuclear factor I binding site emerging in transplant-transmitted fulminant hepatitis B. *Hepatology* (1997) **25**, 1507-1515.
17. Pollicino T, Zanetti AR, Cacciola I, Petit MA, Smedile A, Campo S, Sagliocca L, Pasquali M, Tanzi E, Longo G and Raimondo G: Pre-S2

- defective hepatitis B virus infection in patients with fulminant hepatitis. *Hepatology* (1997) **26**, 495-499.
18. Machida A, Kishimoto S, Ohnuma H, Baba K, Ito Y, Miyamoto H, Funatsu G, Oda K, Usuda S, Togami S, Nakamura T, Miyakawa Y and Mayumi M: A polypeptide containing 55 amino acid residues coded by the pre-S region of hepatitis B virus deoxyribonucleic acid bears the receptor for polymerized human as well as chimpanzee albumins. *Gastroenterology* (1984) **86**, 910-918.
 19. Neurath AR, Kent SB, Strick N and Parker K: Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. *Cell* (1986) **46**, 429-436.
 20. Pontisso P, Petit MA, Bankowski MJ and Peeples ME: Human liver plasma membranes contain receptors for the hepatitis B virus pre-S1 region and, via polymerized human serum albumin, for the pre-S2 region. *J Virol* (1989) **63**, 1981-1988.
 21. Lau JY and Wright TL: Molecular virology and pathogenesis of hepatitis B. *Lancet* (1993) **342**, 1335-1340.
 22. Fernholz D, Galle PR, Stemler M, Brunetto M, Bonino F and Will H: Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. *Virology* (1993) **194**, 137-148.
 23. Okamoto H, Imai M, Tsuda F, Tanaka T, Miyakawa Y and Mayumi M: Point mutation in the S gene of hepatitis B virus for a d/y or w/r subtypic change in two blood donors carrying a surface antigen of compound subtype adyr or adwr. *J Virol* (1987) **61**, 3030-3034.